Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesNSE:THYROCARE +0.05%89 PS Ratio is 10.59 as of Jul. 29, 2026, which is 34% above its 10-year median of 7.90. GuruFocus rates NSE:THYROCARE with a GF Score™ of 89/100 and a GF Value™ of ₹414.13 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Thyrocare Technologies ranks worse than 85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Thyrocare Technologies's share price is ₹580.00.
Thyrocare Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹54.75. Hence, Thyrocare Technologies's PS Ratio for today is 10.59.
Warning Sign:
Thyrocare Technologies Ltd stock PS Ratio (=10.59) is close to 3-year high of 11.03.
The historical rank and industry rank for Thyrocare Technologies's PS Ratio or its related term are showing as below:
NSE:THYROCARE'
s PS Ratio Range Over the Past 10 Years
Min: 4.41 Med: 7.9 Max: 15.82
Current: 10.6
During the past 13 years, Thyrocare Technologies's highest PS Ratio was 15.82. The lowest was 4.41. And the median was 7.90.
NSE:THYROCARE's PS Ratio is ranked worse than 85% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.755
vs NSE:THYROCARE: 10.60
Thyrocare Technologies Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Thyrocare Technologies was 22.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.40% per year.
During the past 13 years, Thyrocare Technologies's highest 3-Year average Revenue per Share Growth Rate was 26.40% per year. The lowest was 5.00% per year. And the median was 16.50% per year.
Back to Basics: PS Ratio
Thyrocare Technologies (NSE:THYROCARE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: PS Ratio Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Thyrocare Technologies's Share Price of today is ₹580.00. Thyrocare Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹54.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Thyrocare Technologies (NSE:THYROCARE) has a PS Ratio of 10.59 as of Jul. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Thyrocare Technologies and its competitors. This is 34% above median its historical median of 7.90. Over the past decade, Thyrocare Technologies' PS Ratio has ranged from 4.41 to 15.82. According to the industry distribution chart, Thyrocare Technologies ranks #170 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 85%.
Is Thyrocare Technologies' PS Ratio too high?
Thyrocare Technologies' current PS Ratio of 10.59 is 34% above median its 10-year median of 7.90. Over the past 10 years, this metric has ranged from a low of 4.41 to a high of 15.82. The Medical Diagnostics & Research industry median PS Ratio is 2.76. Thyrocare Technologies' value of 10.59 is 284.4% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #170 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #170 out of 200 companies for PS Ratio. This places Thyrocare Technologies in the lower half of its industry. The industry median PS Ratio is 2.76. Thyrocare Technologies' value of 10.59 is 284.4% above this benchmark. Historically, Thyrocare Technologies' own PS Ratio has ranged from 4.41 to 15.82 over the past decade. While the company's 10-year median is 7.90 vs. the industry median of 2.76, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.76, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current PS Ratio of 10.59 is 284.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current PS Ratio is 10.59, which is 34% above median its own 10-year median of 7.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹414.13, compared to a current price of ₹580.00 — trading 40.1% above its estimated fair value. The current PS Ratio is 10.59, which is 34% above median its 10-year median of 7.90 and 284.4% above the Medical Diagnostics & Research industry median of 2.76. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current PS Ratio is 10.59 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹580.00 is trading 40.1% above its estimated GF Value™ of ₹414.13.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
PS Ratio: 10.59 (34% above median its 10-year median of 7.90)
GF Value™: ₹414.13 vs. price of ₹580.00 (40.1% above fair value)
Industry Position: 284.4% above the Medical Diagnostics & Research median (#170 of 200)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score
Get the complete analysis for NSE:THYROCARE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
